. 2020 Feb 2;11(1):9–22. doi: 10.14740/wjon1225

Table 2. Baseline Characteristics According to PMI.

	PMI		P
	High	Low	P
N	21	53
Backgrounds
Sex (N)
Male/female	13/8	35/18	0.79^a
Age (years)
Median (IQR)	70 (61 - 73)	69 (63 - 74)	0.61^b
< 70/≥ 70 years (N)	10/11	27/26	1.00^a
Smoking status
NS/Ex, CS	5/16	10/43	0.75^a
Histology
Non-SQ/SQ	18/3	37/16	0.24^a
EGFR mutation
(+)/(-) or NA	3/18	8/45	1.00^a
PD-L1 status
≥ 50%/1-49%/< 1%/NA	3/5/0/13	10/10/8/25	0.25^a
ECOG-PS
0 - 1/2/3	15/4/2	38/12/3	0.82^a
Metastatic sites
< 3/≥ 3	8/13	27/26	0.44^a
BMI
Median (IQR)	24.5 (21.5 - 27.7)	22.0 (19.8 - 23.8)	0.02^a
PMI
Median (IQR)
Male	7.73 (6.82 - 7.85)	4.29 (3.49 - 5.60)	< 0.01^b
Female	4.61 (4.22 - 4.88)	3.27 (2.99 - 3.49)	< 0.01^b
Treatment
ICI regimen (N)
Nivo/Pem/Atezo	17/3/1	40/9/4	1.00^a
Previous treatment (N)
Anti-angiogenic drug	12	22	0.30^a
Radiotherapy	5	14	1.00^a
Further line treatment (N)	13	24	0.30^a
ICI efficacy
CR/PR/SD/PD/NE	1/0/5/15/0	2/8/10/28/5
ORR (%) (95% CI)	4.8 (0.1 - 23.8)	18.9 (9.4 - 32.0)	0.16^a
DCR (%) (95% CI)	28.6 (11.3 - 52.2)	37.7 (24.8 - 52.1)	0.59^a
Laboratory data
NLR
Median (IQR)	2.79 (2.00 - 3.66)	3.57 (2.10 - 4.88)	0.36^b
≤ 5/> 5 (N)	17/4	40/13	0.76^a
Albumin (g/dL)
Median (IQR)	3.6 (3.2 - 3.9)	3.5 (3.2 - 3.9)	0.67^b
≥ 3.5/< 3.5 g/dL (N)	13/8	32/21	1.00^a

^aFisher’s exact test. ^bMann-Whitney U test. Atezo: atezolizumab; BMI: body mass index; CI: confidence interval; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; Ex: ex-smoker; ICI: immune-checkpoint inhibitors; IQR: interquartile range; NE: not evaluated; Nivo: nivolumab; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PD-L1: Programmed cell Death ligand 1; Pem: pembrolizumab; PMI: psoas muscle index; PR: partial response; SD: stable disease; SQ: squamous cell carcinoma; TPS: tumor proportion score.